PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL by A. Sharp, A. Williams, S. Blagden, R. Plummer, D. Hochhauser, M. G. Krebs, S. Pacey, J. Evans, S. Whelan, S. Nandakumar, S. Rogers, K. L. Jameson, F. G. Basile, J. de Bono, H.-T. Arkenau

Get full text

Author Correction: Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population by C. B. Westphalen, M. G. Krebs, C. Le Tourneau, E. S. Sokol, S. L. Maund, T. R. Wilson, D. X. Jin, J. Y. Newberg, D. Fabrizio, L. Veronese, M. Thomas, F. de Braud

Get full text

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population by C. B. Westphalen, M. G. Krebs, C. Le Tourneau, E. S. Sokol, S. L. Maund, T. R. Wilson, D. X. Jin, J. Y. Newberg, D. Fabrizio, L. Veronese, M. Thomas, F. de Braud

Get full text